Neurobiological Markers of Treatment Response for Anxiety and OCD

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorHaukeland University Hospital

About this trial

Obsessive-compulsive disorder (OCD) and anxiety disorders are common and debilitating conditions which are often chronic when treatment is not provided. International guidelines recommend cognitive behavioral therapy (CBT) as the first-line treatment, and research has shown that CBT can be delivered over a concentrated period of time. The Bergen 4-Day Treatment (B4DT) is an exposure-based treatment which is delivered over four consecutive days. B4DT has been shown to induce rapid and long-lasting remission in around 70% of patients. This provides a platform for studying psychological and neurobiological changes associated with treatment response and non-response. The present study will investigate longitudinal changes in psychological measures and DNA methylation in patients who receive the B4DT, as well as a subset will also undergo multimodal brain imaging.

Eligibility criteria

Qualifiers

Diagnosed with obsessive-compulsive disorder, panic disorder or social anxiety disorder using DSM-5 criteria

Referred to National Clinic for 4-Day Treatment, Haukeland University Hospital, Bergen, Norway

Consented to participate in the "Kvalitetsregister for konsentrerte behandlingsformat"

Disqualifiers

Suicidal, ongoing mania, primary eating disorder, intellectual disability, ongoing psychosis, ongoing substance abuse

Trial design

Treatments tested in this trial

  • Bergen 4-Day Treatment (B4DT)

Treatment groups

500 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Haukeland University Hospital

Lead sponsor

University of Oslo

Collaborator

Amsterdam UMC, location VUmc

Collaborator

University of North Carolina, Chapel Hill

Collaborator

Harvard Medical School (HMS and HSDM)

Collaborator

University of Bergen

Collaborator

Oslo University Hospital

Collaborator